|
Extramural Support
|
RMS2013 [E]
|
$366,054,072
|
$157,367
|
N/A
|
National Cancer Institute
|
|
Center for Research to Optimize Precision Lung Cancer Screening in Diverse Populations
|
1UM1CA221939-01
|
$3,139,491
|
|
RITZWOLLER, DEBRA
|
KAISER FOUNDATION RESEARCH INSTITUTE
|
|
Evaluating How Tobacco Control Policies are Shaping the Nicotine Delivery Market
|
5P01CA200512-03
|
$2,893,402
|
|
CUMMINGS, KENNETH
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Immunity and Stress (RESPOND)
|
1U19CA214253-01A1
|
$2,836,742
|
|
HAIMAN, CHRISTOPHER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Pediatric Brain Tumor Consortium (PBTC)
|
5UM1CA081457-20
|
$2,711,850
|
|
ONAR-THOMAS, ARZU
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Life Course Cancer Epidemiology Cohort in Women
|
2U01CA176726-06
|
$2,423,825
|
|
WILLETT, WALTER
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
|
Mayo Clinic Hepatobiliary SPORE
|
1P50CA210964-01A1
|
$2,300,000
|
|
MC NIVEN, MARK
|
MAYO CLINIC ROCHESTER
|
|
DRUG DELIVERY SYSTEM TO SAVE HEARING DURING PEDIATRIC CHEMOTHERAPY REGIMENS. POP 8/30/2018 - 08/28/2020.
|
261201700023C
|
$1,999,787
|
$1,999,787
|
SHIMOJI PHD, MIKA
|
OTOMAGNETICS, LLC
|
|
Detroit Research on Cancer Survivors (Detroit ROCS)
|
5U01CA199240-02
|
$1,995,543
|
|
SCHWARTZ, ANN
|
WAYNE STATE UNIVERSITY
|
|
Interleukin-15 Production for Treatment of Patients with Metastatic Malignancy
|
ZIB BC 010906
|
$1,949,215
|
$1,949,215
|
Waldmann, Thomas
|
CCR (NCI)
|
|
NK cells, their receptors, transplantation and cancer therapy
|
5P01CA111412-13
|
$1,814,553
|
|
MILLER, JEFFREY
|
UNIVERSITY OF MINNESOTA
|
|
Integrated EGFR function in cytokine-driven inflammation and cancer
|
5P01CA062220-23
|
$1,805,475
|
$180,548
|
STARK, GEORGE
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies
|
ZIA BC 008753
|
$1,671,202
|
$1,671,202
|
Pastan, Ira
|
CCR (NCI)
|
|
Genetic Modifiers of Initiation and Progression of Mammary Cancer
|
ZIA BC 011255
|
$1,639,741
|
|
Hunter, Kent
|
CCR (NCI)
|
|
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies
|
ZIA BC 008753
|
$1,606,820
|
$1,606,820
|
Pastan, Ira
|
CCR (NCI)
|
|
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms
|
5U01CA200466-03
|
$1,563,388
|
|
BRAND, RANDALL
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
IGF::OT::IGF
|
261201800038C
|
$1,499,993
|
|
-, -
|
INTELLIGENT AUTOMATION, INC.
|
|
IGF::OT::IGF
|
261201800047C
|
$1,499,914
|
|
-, -
|
CHARLES RIVER ANALYTICS, INC.
|
|
SmartStop: Programmable Transdermal Nicotine Replacement Therapy
|
4R44CA171786-02
|
$1,463,029
|
$1,463,029
|
Chang, Kuowei
|
CHRONO THERAPEUTICS, INC.
|
|
Interleukin-15 Production for Treatment of Patients with Metastatic Malignancy
|
ZIB BC 010906
|
$1,388,882
|
$1,388,882
|
Waldmann, Thomas
|
CCR (NCI)
|
|
H. pylori-Induced Inflammation and gastric cancer
|
5P01CA116087-11
|
$1,384,046
|
|
PEEK, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Intraoperative Near-Infrared Fluorescence Imaging
|
5R01CA115296-09
|
$1,362,767
|
$1,362,767
|
Frangioni, John
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Growth Factor Imaging
|
ZIA BC 010656
|
$1,320,390
|
$396,117
|
Choyke, Peter
|
CCR (NCI)
|
|
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas
|
5P01CA069246-21
|
$1,316,832
|
|
BREAKEFIELD, XANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
INFORMATION TECHNOLOGY SERVICES AND SUPPORT PROJECT
|
N01CA100079
|
$1,300,000
|
$1,300,000
|
UNKNOWN, UNKNOWN
|
INFORMATION MANAGEMENT SERVICES, INC.
|
|
DNA Vaccines
|
ZIA BC 010749
|
$1,293,663
|
$64,683
|
Pavlakis, George
|
CCR (NCI)
|
|
Vascular Biology Section
|
ZIA BC 011390
|
$1,186,781
|
|
Lin, Pengnian Charles
|
CCR (NCI)
|
|
Great Lakes New England Clinical Validation Center
|
5U01CA086400-18
|
$1,178,448
|
|
BRENNER, DEAN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Protein Structure
|
ZIA BC 010348
|
$1,173,857
|
|
Wlodawer, Alexander
|
CCR (NCI)
|
|
Immunohistochemical analysis of tumors
|
ZIA BC 011427
|
$1,154,730
|
|
Miettinen, Markku
|
CCR (NCI)
|
|
Regulation of ADP-ribosylation factor
|
ZIA BC 007365
|
$1,141,796
|
|
Randazzo, Paul
|
CCR (NCI)
|
|
EndoPulse System for Endoscopic Ultrasound-Guided Therapy of Pancreatic Carcinoma
|
5R44CA150484-03
|
$1,141,554
|
$1,141,554
|
NUCCITELLI, RICHARD
|
BIOELECTROMED CORPORATION
|
|
Rewired Signaling at the Nexus of Melanoma Metastasis and Resistance
|
5R35CA197465-03
|
$1,135,587
|
|
RONAI, ZE'EV
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
Lambda Genetic Networks and Lambda Red-Mediated Recombination
|
ZIA BC 010336
|
$1,133,603
|
$283,401
|
Court, Donald
|
CCR (NCI)
|
|
Development and Preclinical Applications of Pancreatic Adenocarcinoma Models
|
ZIA BC 011739
|
$1,126,602
|
|
Sharan, Shyam
|
CCR (NCI)
|
|
Consequences of chronic Interferon-gamma expression on the host
|
ZIA BC 009283
|
$1,117,083
|
|
Young, Howard
|
CCR (NCI)
|
|
Prostate Cancer Imaging
|
ZIA BC 010655
|
$1,100,325
|
$220,065
|
Choyke, Peter
|
CCR (NCI)
|
|
Breast, Colorectal, and Ovary Cancer Clinical Validation Center
|
5U01CA152637-08
|
$1,085,901
|
|
LI, CHRISTOPHER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Search for the Structural Basis of Biomacromolecular Function and Activity
|
ZIA BC 010379
|
$1,058,665
|
$158,800
|
Wang, Yun-Xing
|
CCR (NCI)
|
|
Biomolecular Structure and Mechanism, Structure-Based Drug Design
|
ZIA BC 010326
|
$1,047,882
|
$1,047,882
|
Ji, Xinhua
|
CCR (NCI)
|
|
Innovative Device to Improve Safety of Preparing and Administering Chemotherapy
|
5R44CA153636-03
|
$1,014,171
|
$1,014,171
|
Sunkara, Prasad
|
J AND J SOLUTIONS, INC.
|
|
Cellular Interactions with Thrombospondin
|
ZIA SC 009172
|
$1,003,208
|
|
Roberts, David
|
CCR (NCI)
|
|
SBIR Phase II: Low-Cost Microfluidic System for Detection of CTC's.
|
N44CO130071-000
|
$999,873
|
$999,873
|
HUPERT, MATEUSZ
|
BIOFLUIDICA MICROTECHNOLOGIES LLC
|
|
SBIR Phase II Topic 293: Point of Care Device for Antibody Independent Isolation
|
N44CO130070-000
|
$999,750
|
$999,750
|
DAVIS, DARREN
|
APOCELL, INC.
|
|
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes
|
ZIA BC 010801
|
$969,834
|
|
Widemann, Brigitte
|
CCR (NCI)
|
|
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
|
5R35CA197442-02
|
$951,000
|
|
MARKOWITZ, SANFORD
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Molecular Chaperones and DNA Replication
|
ZIA BC 008710
|
$945,830
|
$945,830
|
Wickner, Sue
|
CCR (NCI)
|
|
Commercialization of Magneto-Nanosensor Immunoassay Platform for Cancer Diagnosis
|
2R44CA165296-02
|
$940,623
|
$940,623
|
Carbonell, Manuel
|
MAGARRAY, INC.
|
|
Therapeutic evaluation in ovarian and breast cancer GEM/GDA models
|
ZIA BC 011737
|
$938,835
|
|
Sharan, Shyam
|
CCR (NCI)
|
|
Design and Utility of Novel Proteinaceous Biomaterials
|
ZIA BC 011313
|
$930,398
|
$837,358
|
Schneider, Joel
|
CCR (NCI)
|
Total relevant funding to Bioengineering for this search: $169,110,979
|